ECSP088842A - Metodo para inhibir la cinasa del c?kit - Google Patents

Metodo para inhibir la cinasa del c?kit

Info

Publication number
ECSP088842A
ECSP088842A EC2008008842A ECSP088842A ECSP088842A EC SP088842 A ECSP088842 A EC SP088842A EC 2008008842 A EC2008008842 A EC 2008008842A EC SP088842 A ECSP088842 A EC SP088842A EC SP088842 A ECSP088842 A EC SP088842A
Authority
EC
Ecuador
Prior art keywords
kit
inhibiting
kink
subject
present
Prior art date
Application number
EC2008008842A
Other languages
English (en)
Inventor
Carl Illig
Shelley Ballentine
Jinsheng Chen
Sanath Meegalla
M Jonathan Rudolph
Mark Wall
Renee Louise Desjarlais
Carl Manthey
Christopher Flores
Kenneth Wilson
Christopher J Molloy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP088842A publication Critical patent/ECSP088842A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método para reducir o inhibir la actividad de la cinasa del C?KIT en una célula o un sujeto, y el uso de tales compuestos para prevenir o tratar en un sujeto un trastorno proliferativo celular y/o trastornos relacionados con el C?KIT, utilizando un compuesto de la presente invención:o un solvato, hidrato, tautómero o sal farmacéuticamente aceptable del mismo; la presente invención está dirigida además a métodos para tratar condiciones tales como cánceres y otros trastornos proliferativos celulares.
EC2008008842A 2006-04-20 2008-10-22 Metodo para inhibir la cinasa del c?kit ECSP088842A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79347106P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
ECSP088842A true ECSP088842A (es) 2008-11-27

Family

ID=38625740

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008842A ECSP088842A (es) 2006-04-20 2008-10-22 Metodo para inhibir la cinasa del c?kit

Country Status (22)

Country Link
EP (2) EP2397138B1 (es)
JP (1) JP5595727B2 (es)
KR (1) KR101448052B1 (es)
CN (2) CN102670605B (es)
AU (1) AU2007240400B2 (es)
BR (1) BRPI0710542B8 (es)
CA (1) CA2649755C (es)
CO (1) CO6382175A2 (es)
CR (1) CR10450A (es)
EA (1) EA016611B1 (es)
EC (1) ECSP088842A (es)
ES (2) ES2389678T3 (es)
GT (1) GT200800225A (es)
HK (1) HK1124766A1 (es)
IL (1) IL194846A (es)
MX (1) MX2008013528A (es)
MY (1) MY147226A (es)
NO (1) NO342001B1 (es)
NZ (1) NZ572200A (es)
SG (1) SG171592A1 (es)
WO (1) WO2007124369A2 (es)
ZA (1) ZA200809874B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5944503B2 (ja) 2011-07-27 2016-07-05 エービー サイエンス 選択的プロテインキナーゼ阻害剤
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
TWI630205B (zh) 2013-07-22 2018-07-21 瑞士商愛杜西亞製藥有限公司 １－（哌－１－基）－２－（［１，２，４］三唑－１－基）－乙酮衍生物
HUE042559T2 (hu) 2015-01-15 2019-07-29 Idorsia Pharmaceuticals Ltd Hidroxialkil-piperazin származékok mint cxcr3 receptor modulátorok
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
CN105753770A (zh) * 2015-05-27 2016-07-13 上海佐林生物医药有限公司 蛋白激酶抑制剂制备方法、中间体、制备方法及应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP1185559A2 (en) 1999-04-28 2002-03-13 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
CA2494695C (en) * 2002-08-02 2011-04-05 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
EP1684750B1 (en) * 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
EP1711497A1 (en) * 2004-01-30 2006-10-18 AB Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
MX2007004784A (es) * 2004-10-22 2007-09-11 Johnson & Johnson Inhibidores de la c-fms cinasa.
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
CA2626623C (en) * 2005-10-18 2016-08-30 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
AU2006342509A1 (en) * 2006-04-20 2007-11-01 Janssen Pharmaceutica, N.V. c-fms kinase inhibitors
KR101367645B1 (ko) * 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물
EP2016070B1 (en) * 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase

Also Published As

Publication number Publication date
BRPI0710542B8 (pt) 2021-05-25
NO342001B1 (no) 2018-03-12
NZ572200A (en) 2011-09-30
EA200870454A1 (ru) 2009-04-28
IL194846A (en) 2015-07-30
EP2015748B1 (en) 2012-07-04
BRPI0710542A2 (pt) 2012-06-05
CN101610768A (zh) 2009-12-23
EP2015748A2 (en) 2009-01-21
AU2007240400B2 (en) 2013-08-22
CN102670605A (zh) 2012-09-19
SG171592A1 (en) 2011-06-29
CN102670605B (zh) 2015-07-29
CN101610768B (zh) 2012-03-21
JP2009534418A (ja) 2009-09-24
ZA200809874B (en) 2010-02-24
CA2649755A1 (en) 2007-11-01
GT200800225A (es) 2009-05-15
CO6382175A2 (es) 2012-02-15
BRPI0710542B1 (pt) 2021-01-12
MX2008013528A (es) 2008-10-29
EP2397138B1 (en) 2013-12-11
HK1124766A1 (en) 2009-07-24
AU2007240400A1 (en) 2007-11-01
IL194846A0 (en) 2009-08-03
ES2458291T3 (es) 2014-04-30
WO2007124369A3 (en) 2008-03-06
KR20080111545A (ko) 2008-12-23
WO2007124369A2 (en) 2007-11-01
JP5595727B2 (ja) 2014-09-24
KR101448052B1 (ko) 2014-10-07
MY147226A (en) 2012-11-14
NO20084892L (no) 2009-01-06
EA016611B1 (ru) 2012-06-29
CR10450A (es) 2009-02-23
ES2389678T3 (es) 2012-10-30
CA2649755C (en) 2014-12-02
EP2397138A1 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
ECSP088842A (es) Metodo para inhibir la cinasa del c?kit
CR9984A (es) Método de inhibición de cinasa de tirosina cinasa 3 similar a fms
ME00936B (me) Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
NI201500128A (es) 3- pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
MX2009009786A (es) Inhibidores de la via de hedgehog.
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
NI201400026A (es) 3 - pirimidin - 4 - il - oxazolidin - 2 - onas como inhibidores de la idh mutante.
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
WO2007149427A3 (en) Tyrosine kinase inhibitors
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
WO2013188813A3 (en) Novel therapeutics for brain cancer
AR086444A1 (es) Composiciones farmaceuticas y metodos para tratar el cancer
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
MX2011012522A (es) Inhibidores de pirazol sustituido de proteina cinasa c-met.
MX2011012524A (es) Inhibidores de proteina cinasa c-met.
EA201270347A1 (ru) Производные апогоссиполона в качестве противоопухолевых агентов
PT2435443E (pt) Inibidores à base de aminopirazole triazolotiadiazole da proteína quinase c met
WO2016106357A8 (en) Combination of raf inhibitors and aurora kinase inhibitors
UA99612C2 (en) Inhibitors of the hedgehog pathway
UA105483C2 (uk) Похідні ізохінолінону, композиція на їх основі та застосування як інгібіторів рі3k